No Data
No Data
No Data
No Data
No Data
Express News | Spyre Therapeutics Inc : Baird Initiates Coverage With Outperform Rating; Target Price $50
ReutersMay 2 02:31 ET
Spyre Therapeutics Files to Sell 33.36M Shares of Common Stock for Holders
Seeking AlphaApr 19 12:24 ET
Sector Update: Health Care Stocks Steady Pre-Bell Friday
Health care stocks were steady pre-bell Friday, with the Health Care Select Sector SPDR Fund (XLV) inactive and the iShares Biotechnology ETF (IBB) recently down 0.1%. Sanofi (SNY) is reportedly plann
MT NewswiresApr 19 09:12 ET
Express News | Spyre Therapeutics Inc Files for Offering of up to 33.4 Mln Common Shares by the Selling Stockholders - SEC Filing
Moomoo 24/7Apr 19 06:06 ET
Buy Rating Affirmed for Spyre Therapeutics on Promising MAb Dosing and Market Positioning
TipRanksApr 5 07:55 ET
Stifel Adjusts Spyre Therapeutics' Price Target to $54 From $36, Maintains Buy Rating
Spyre Therapeutics (SYRE) has an average rating of buy and price targets ranging from $31 to $54, according to analysts polled by Capital IQ. Price: 37.76, Change: -0.72, Percent Change: -1.87
MT NewswiresMar 26 10:37 ET
No Data
No Data
BelleWeather : GILD is down .03%, or two cents. Two pennies. That is not a remarkable fall.
71731595 BelleWeather: Remarkable
DudeThatsDerpy : Sheesh. The spelling errors in this article make it feel less reliable.